Rosen Law Firm sets Sept. 28 deadline in Capricor investor suit
Rosen Law Firm says investors in Capricor Therapeutics who bought securities during a stated class period have until Sept. 28 to seek appointment as lead plaintiff in a filed securities fraud lawsuit.
Rosen Law Firm said Capricor Therapeutics investors who bought CAPR securities between Dec. 17, 2025, and July 26, 2026, may seek to lead a securities fraud class action. The deadline to apply is Sept. 28, 2026.
The notice, issued Sept. 3, said a class action lawsuit has already been filed and that investors may be entitled to compensation under a contingency fee arrangement without paying out-of-pocket fees or costs. It also said no class has been certified yet.
Rosen said the lead plaintiff helps direct the case on behalf of other class members. Investors who do not seek that role may still share in any potential recovery if the case moves forward.
In its case description, the notice said the lawsuit alleges Capricor and/or defendants made materially false or misleading statements or failed to disclose several issues tied to Deramiocel, including a change to the pre-specified statistical analysis plan, the FDA's alleged lack of agreement to those changes before Capricor resubmitted the Deramiocel Biologics License Application, and what the complaint describes as a significant risk that the clinical results would be viewed as insufficient to show effectiveness.
The notice also said the lawsuit alleges there was substantial risk to regulatory approval of Deramiocel for Duchenne muscular dystrophy and that positive statements about Capricor's business, operations and prospects were materially misleading or lacked a reasonable basis. The notice did not provide independent verification of those claims and attributed them to the lawsuit.
Rosen said investors may join the action through a Rosen Legal webpage, by calling Phillip Kim, Esq. toll-free at 866-767-3653, or by emailing [email protected]. The notice said investors are not represented by counsel unless they retain one and may choose their own lawyer or do nothing at this stage.
The Sept. 28 lead-plaintiff deadline is the next date listed in the notice. The class period runs from Dec. 17, 2025, through July 26, 2026, and the notice says investors' ability to share in any future recovery does not depend on serving as lead plaintiff.
Sources
Editorial note: This article was prepared with AI assistance and includes source attribution for reader review.
Comments ()